Delmar Pharmaceuticals, Inc. and Adgero Biopharmaceuticals Holdings, Inc. Announce Combined Company Management Appointments
June 10, 2020 at 01:52 pm
Share
On June 9, 2020, DelMar Pharmaceuticals, Inc. (the Company), Adgero Acquisition Corp., a wholly-owned subsidiary of DelMar incorporated in the State of Delaware (Merger Sub), and Adgero Biopharmaceuticals Holdings, Inc., a Delaware corporation (Adgero), entered into an Agreement and Plan of Merger and Reorganization (the Merger Agreement) pursuant to which Merger Sub will merge with and into Adgero, with Adgero surviving the merger and becoming a direct, wholly-owned subsidiary of DelMar (the Merger). Following the Merger, if approved by the stockholders, DelMar will be renamed Kintara Therapeutics, Inc. The Merger is expected to be completed in the third calendar quarter of 2020. At the Effective Time, the Merger Agreement contemplates that the board of directors of the Company will consist of up to seven members, four of whom will be directors designated by the Company, two of whom will be directors nominated by Adgero and approved by DelMar and one of whom will be an independent director mutually agreed to by the companies. Immediately after the Effective Time, Saiid Zarrabian, President and Chief Executive Officer of DelMar, will continue to serve as President and Chief Executive Officer of the combined company, John Liatos, the interim Chief Executive Officer and Chief Financial Officer of Adgero, will be Senior Vice President, Business Development of the combined company, Scott Praill, Chief Financial Officer of DelMar, will continue to serve as Chief Financial Officer of the combined company, Dennis Brown, Chief Scientific Officer of DelMar will continue to serve as Chief Scientific Officer of the combined company, and Steve Rychnovsky, Vice President, Operations and Product Development of Adgero, will be Vice President, Research and Development of the combined company.
Kintara Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development and commercialization of new cancer therapies. It is focused on the development of novel cancer therapies for patients with unmet medical needs. Its two candidates include VAL-083 and REM-001. VAL-083 is a novel, validated, deoxyribonucleic acid (DNA)-targeting agent, for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme (GBM) and potentially other solid tumors, including ovarian cancer, non-small cell lung cancer (NSCLC), and diffuse intrinsic pontine glioma (DIPG). REM-001 is a late-stage photodynamic therapy (PDT) for the treatment of cutaneous metastatic breast cancer (CMBC), basal cell carcinoma nevus syndrome (BCCNS), and access graft failure in hemodialysis patients. VAL-083 is being evaluated in all three GBM patient subtypes in the GBM AGILE Study: newly diagnosed methylated MGMT; newly diagnosed unmethylated MGMT, and recurrent.
KINTARA THERAPEUTICS, INC. 
